Molecular Formula | C19H18O3 |
Molar Mass | 294.34 |
Density | 1.128±0.06 g/cm3(Predicted) |
Melting Point | 120-122 °C(Solv: ethanol (64-17-5); water (7732-18-5)) |
Boling Point | 467.2±40.0 °C(Predicted) |
Storage Condition | 2-8°C |
Use | TFEB activator 1 is an orally effective, mTOR-independent TFEB activator. TFEB activator 1 significantly promoted nuclear translocation of Flag-TFEB with EC50 of 2167 nM. TFEB activator 1 enhances autophagy (autophagy) without inhibiting mTOR pathway. TFEB activator 1 has the potential to be used in the study of neurodegenerative diseases. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 3.397 ml | 16.987 ml | 33.974 ml |
5 mM | 0.679 ml | 3.397 ml | 6.795 ml |
10 mM | 0.34 ml | 1.699 ml | 3.397 ml |
5 mM | 0.068 ml | 0.34 ml | 0.679 ml |
biological activity | currumin analog C1 (Curcumin analog Compound C1) is a potent activator of transcription factor EB (TFEB), it is expected to be used for the prevention or treatment of Alzheimer's disease. |
Target | Value |
Cell Line: | N2a cells |
Concentration: | 0, 0.2, 0.4, 0.6, 0.8 and 1 μM |
Incubation Time: | 12 hours |
Result: | Treatment dose-dependently increased the levels of LC3-II and SQSTM1/p62 (sequestosome 1). Activated TFEB and enhanced autophagy and lysosome biogenesis in rat brain. Activated TFEB and enhanced autophagy in rat brains. |
Animal Model: | Adult male Sprague-Dawley (SD) rats weighing 350 to 400 g Adult male Sprague-Dawley (SD) rats weighing 350 to 400 g |
Dosage: | 10 mg/kg and 25 mg/kg 10 mg/kg |
Administration: | Short-term oral administration; for 24 hours Chronic oral administration; daily; for 21 days |